Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma [0.03%]
潘生丁用于治疗复发性皮肤T细胞淋巴瘤的潜在疗效证据评估
Brian Poligone,Janet Lin,Catherine Chung
Brian Poligone
Introduction: Cutaneous T cell lymphoma (CTCL) encompasses a heterogeneous group of neoplasms of skin-homing T cells, which includes mycosis fungoides, the most common form, and Sézary syndrome, the leukemia equivalent o...
Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting [0.03%]
关于福司匹利和阿瑞匹坦在化疗引起的恶心呕吐预防中的证据更新及定位评论
Patrick Langford,Paul Chrisp
Patrick Langford
Introduction: The selective neurokinin-1 receptor antagonist aprepitant is effective in the treatment of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with both moderately and highly emetoge...
Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer [0.03%]
帕尼单抗在转移性结直肠癌治疗中的应用证据
Rossana Berardi,Azzurra Onofri,Mirco Pistelli et al.
Rossana Berardi et al.
Panitumumab is the first fully human monoclonal antibody to Epidermal Growth Factor Receptor (EGFR) to enter clinical trials for the treatment of solid tumors. The anti-tumor activity of panitumumab has been tested in vitro and in vivo, and...
Dronedarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation [0.03%]
达non达rone在治疗房颤中的应用证据
Renee M Sullivan,Brian Olshansky
Renee M Sullivan
Introduction: Dronedarone, a benzofuran derivative with a structure similar to amiodarone, has been developed as a potential therapy for patients with atrial fibrillation. ...
Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review [0.03%]
基于循证的达菲能素α-2b作为III期黑色素瘤辅助治疗药物的疗效分析
Sonia Okuyama,Rene Gonzalez,Karl D Lewis
Sonia Okuyama
Introduction: Stage III melanoma, also referred to as regional metastatic melanoma, has five-year survival rates ranging between 40% and 78%. In order to reduce the likelihood of recurrence in this high-risk population, p...
Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus [0.03%]
萨格列汀治疗2型糖尿病的证据分析
Kristen Kulasa,Steven Edelman
Kristen Kulasa
Introduction: The worldwide prevalence of type 2 diabetes mellitus (T2DM) is high, and the chronically poor metabolic control that can result from T2DM is associated with a high risk for microvascular and macrovascular co...
Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis [0.03%]
乌司奴单抗：其治疗银屑病有效性的循证评价
Eliana Krulig,Kenneth B Gordon
Eliana Krulig
Introduction: Psoriasis is a chronic inflammatory skin disease affecting approximately 2% to 3% of the population worldwide. Discoveries over the past 3 to 5 years have significantly altered our view of psoriasis as prima...
Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease [0.03%]
卡比多巴/左旋多巴/恩他卡朋：治疗帕金森病的证据及其地位分析
Markos Poulopoulos,Cheryl Waters
Markos Poulopoulos
Introduction: Parkinson's disease (PD) is a common neurodegenerative disease. In the 1960s, it was shown that the degeneration of dopamine producing neurons in the substantia nigra (SN) caused the motor features of PD. Do...
Omalizumab: the evidence for its place in the treatment of allergic asthma [0.03%]
奥马珠单抗：其用于过敏性哮喘治疗地位的证据分析
Diarmuid M McNicholl,Liam G Heaney
Diarmuid M McNicholl
Introduction: Asthma is a chronic inflammatory airways disease associated with reversible airflow obstruction and bronchial hyperresponsiveness. Asthma is prevalent worldwide and results in significant morbidity, mortalit...
Prucalopride: the evidence for its use in the treatment of chronic constipation [0.03%]
普鲁卡洛普治疗慢性便秘的有效性研究证据
Georges Coremans
Georges Coremans
Introduction: Chronic constipation is a common condition that is difficult to treat. Existing options for the treatment of patients with different subgroups of constipation are limited. A new efficacious and safe drug is ...